Barberà, Joan http://orcid.org/0000-0003-1469-4990
Jansa, Pavel
Klings, Elizabeth
Ristić, Arsen
Keogh, Anne
Solum, Derek
Rao, Youlan
Grover, Rob
Saib, Isil
Sood, Namita
Funding for this research was provided by:
United Therapeutics Corporation
Article History
Received: 7 November 2023
Accepted: 12 December 2023
First Online: 10 January 2024
Declarations
:
: Joan Barberà is a consultant and speaker for Janssen-Cilag, Merck Sharp & Dome and Ferrer, consultant for Acceleron Pharma, and has received grants from Janssen-Cilag, Merck Sharp & Dome and Ferrer. Pavel Jansa has received fees and grants from Janssen Pharmaceutical Companies of Johnson and Johnson, AOP Orphan, United Therapeutics, and Merck Sharp & Dohme. He has served as advisory boards member for Janssen Pharmaceutical Companies of Johnson and Johnson, AOP Orphan, and Merck Sharp & Dohme. Elizabeth Klings receives research support from United Therapeutics, Novartis, Bayer, Novo Nordisk/FORMA. She was an advisory board member for Vertex and Global Blood Therapeutics/Pfizer. She is the member of the safety review committee for a phase 1 trial for CSL Behring. Arsen Ristić and Anne Keogh have nothing to disclose. Namita Sood is a member of a speaker bureau for Bayer Pharmaceuticals and was a site PI for ADVANCE. Derek Solum, Youlan Rao, Rob Grover, and Isil Saib are employees of United Therapeutics.
: Written informed consent was obtained from all study subjects, and protocols were approved by the institutional review board at each participating study site. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. A full list of the committees at each study site can be found in the supplement; the central IRB was Western Institutional Review Board (WIRB), which has since updated their name to WCG IRB.